Significant reduction in total allergy symptoms vs PLACEBO at weeks 4, 8, and 12
*Randomized, double-blind study (N=69) in children ages 6-12 years with perennial allergic rhinitis comparing ZYRTEC® 10 mg daily (n=19) and placebo (n=16) over 12 weeks. Primary endpoint was change in mean total symptom score during treatment.
ZYRTEC® significantly improved the mean total symptom score from the baseline level compared with study participants receiving placebo for weeks 4, 8, and 12 (P<0.01). Reference: 1. Lai DS, et al. Ann Allergy Asthma Immunol. 2002;89(6):589-598